Our Company
Our Company

Kye Pharmaceuticals

From registration to commercialization, the Kye team creatively addresses the challenges of the pharmaceutical environment to bring important new medicines to Canadians.

Our Company

Our Leadership TeamBoard of Directors
ProductsPress ReleasesPartneringCareersContact
En
Fr
Home
Our Company

Kye Pharmaceuticals

From registration to commercialization, the Kye team creatively addresses the challenges of the pharmaceutical environment to bring important new medicines to Canadians.

Our Company

Our Leadership TeamBoard of Directors
ProductsPress ReleasesPartneringCareersContact
Featured Post

Health Canada approves Quillivant® ER (extended release) oral suspension and chewable tablets for the treatment of ADHD.

September 25, 2023
Read More

January 5, 2022

Shield Therapeutics and KYE Pharmaceuticals Inc Announce Exclusive licence agreement for development and commercialisation of Accrufer®

Read More

June 3, 2021

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

Read More

May 4, 2021

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)

Read More

January 5, 2021

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets)

Read More

October 28, 2020

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

Read More

August 26, 2020

KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity

Read More
Previous
Next
Follow us on LinkedIn!
Kye Pharmaceuticals © 2023. All Rights Reserved.  |  Web Design by Aquí.
ContactPrivacy PolicyTerms of Use
Kye Pharmaceuticals © 2023. All Rights Reserved.  Web Design by Aquí.